Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
UNIVERSITE CLAUDE BERNARD - LYON 1 is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, providing a diversified examination experience for the company's active applications. The presence of 2 pending actions indicates a consistent but limited level of engagement with the patent office in this field. This distribution suggests that the applicant is pursuing multiple technical threads that are being evaluated independently.
The prosecution is distributed across 2 distinct art units, which suggests that the applications cover different technical niches within the broader biotechnology sector. AEDER, SEAN E is the busiest examiner for the portfolio, with 1 pending office action currently assigned. Because this examiner handles 1 of the 2 pending matters, they are responsible for half of the company's active workload. This structure requires the company to address the unique prior art and legal arguments presented by two different examiners across two distinct administrative groups to advance its patent goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17995809 | USE OF VIDOFLUDIMUS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | HAVLIN, ROBERT H | 31d overdue |
| 18038970 | METHODS FOR DIAGNOSIS AND MONITORING OF TOXIC EPIDERMAL NECROLYSIS | AEDER, SEAN E | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18038970 | METHODS FOR DIAGNOSIS AND MONITORING OF TOXIC EPIDERMAL NECROLYSIS | AEDER, SEAN E | 1642 | §112 | Final Rejection | — | Pending | May 25, 2023 |
| 17995809 | USE OF VIDOFLUDIMUS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | HAVLIN, ROBERT H | 1626 | §103 | Final Rejection | 31d overdue | Pending | Oct 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial